Amycretin vs CagriSema: One Dual Agonist vs Two-Drug Amylin Stack
Amycretin vs CagriSema explained: Novo's unimolecular GLP-1/amylin agonist versus cagrilintide + semaglutide. Dosing formats, early vs Phase 3 data, and what the difference means for patients.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Log this Semaglutide stack in PeptIQ
Track every compound, timing, and dose in one protocol, on web or mobile.
Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist
# Amycretin vs CagriSema: One Dual Agonist vs Two-Drug Amylin Stack
> Note: PeptIQ is not a medical provider. These programs differ in maturity. Educational comparison only.
Novo is playing both sides of the amylin chessboard:
CagriSema — two drugs (cagrilintide + semaglutide)
Amycretin — one drug hitting GLP-1 and amylin receptors
That is the clean SEO comparison: fixed combo vs unimolecular dual agonist.
Architecture Difference
CagriSema
Amycretin
Design
Two molecules
One dual agonist molecule
Amylin piece
Cagrilintide
Built into amycretin
GLP-1 piece
Semaglutide
Built into amycretin
Public maturity
Large Phase 3 obesity dataset (REDEFINE)
Early-phase published; Phase 3 advancing
Formats
Weekly injectable combo story
Oral daily and SC weekly in development
Data Maturity Gap (Be Honest)
CagriSema already has Phase 3 mean weight-loss figures in the ~20% neighborhood for the combo, with clear monotherapy comparators.
Amycretin early SC cohorts showed very large mean losses (public summaries around ~10–22% depending on dose/duration part) in smaller, earlier studies — exciting, not yet Phase 3 confirmed at scale.
Oral amycretin added a short-window ~10–13% signal that made the pill narrative real.
Rule: do not crown amycretin the winner because an early 22% mean looks higher than a Phase 3 20% mean from a different design.
Dosing Mental Models
Program
Public anchors
CagriSema maintenance story
Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly
Amycretin SC early map
Exploratory weekly exposures including 1.25 / 5 / 20 mg
Amycretin oral early map
Daily doses around 50 mg (and higher short-term)
Phase 3 amycretin ladders will replace early maps.
Who Might Prefer Which Architecture (Conceptual)
Fixed two-drug combo (CagriSema-like)
Independent titration of components sometimes possible in research settings
Huge evidence package already accumulating
Familiar semaglutide half for clinicians
Unimolecular dual agonist (amycretin-like)
Single product simplicity
Oral option could matter enormously for adherence
Different PK/PD optimization than bolting two drugs together
Real "preference" will be driven by approval, price, tolerability, and comorbidities — not Twitter diagrams.
What to Track Either Way
Pathway drugs involved (one vs two)
Escalation dates
GI scores
Protein + lifting
Average weight / waist
Missed doses (especially for oral daily)
FAQ
Q: Is amycretin better than CagriSema?
A: Unknown until mature Phase 3 amycretin data and any comparative evidence exist.
Q: Is amycretin just liquid CagriSema?
A: No. Different molecular design.
Q: Does amycretin replace semaglutide?
A: It is a separate investigational dual agonist, not a generic for Ozempic/Wegovy.
Q: Should I switch from CagriSema interest to amycretin hype?
A: Follow evidence tiers. CagriSema is further along in large outcomes packages today.
Bottom Line
Amycretin vs CagriSema is Novo's two answers to GLP-1 + amylin: one pill/injection molecule versus a proven two-drug weekly combo. Learn the architecture, respect the maturity gap, and track whatever you actually use with clean dose logs.
Download PeptIQ to compare protocol eras without losing history.
